var data={"title":"Nystatin and triamcinolone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nystatin and triamcinolone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6673?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nystatin-and-triamcinolone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nystatin and triamcinolone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202905\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Topical;</li>\n      <li>\n        Corticosteroid, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202894\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Cutaneous <i>Candida</i>:</b> Topical: Apply sparingly to affected area(s) twice daily. Therapy should be discontinued when control is achieved or if symptoms persist for &gt;25 days of therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202901\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202895\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50525681\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50525682\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202884\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, External: Nystatin 100,000 units and triamcinolone acetonide 0.1% (15 g, 30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment, External: Nystatin 100,000 units and triamcinolone acetonide 0.1% (15 g, 30 g, 60 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202872\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202887\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">External use only; do not use on open or weeping wounds; do not use with occlusive dressings.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202886\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of cutaneous candidiasis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202879\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Localized burning</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, allergic dermatitis, atrophic striae, folliculitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, skin atrophy, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Secondary infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation, local pruritus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202890\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to nystatin, triamcinolone, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202876\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatitis: Cutaneous hypersensitivity/contact dermatitis to individual ingredients has been reported; instruct patients to seek medical attention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Steroids may mask infection or enhance existing infection; prolonged use may result in secondary infections due to immunosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299779\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202880\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9713&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progesterone: Antifungal Agents (Vaginal) may diminish the therapeutic effect of Progesterone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202881\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287273\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202891\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15788598\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinary free cortisol test, morning plasma cortisol test, and ACTH stimulation test may be used to evaluate HPA axis suppression; signs of improving or worsening <i>Candida</i> or new bacterial infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202875\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202889\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524689\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Nystatin-Triamcinolone External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100000 unit/g 0.1% (30 g): $159.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Nystatin-Triamcinolone External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100000 unit/g 0.1% (30 g): $159.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539904\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fungiderma (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Coulthard P, Horner K, Sloan P, Theaker E, eds. <i>Master dentistry volume 1, Oral and Maxillofacial Surgery, Radiation, Pathology and Oral Medicine.</i> 12th ed. Edinburgh: Churchill Livingstone/Elsevier; 2008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nystatin-and-triamcinolone-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo; <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nystatin-and-triamcinolone-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nystatin and triamcinolone [prescribing information]. Johnson City, TN: Crown Laboratories; received March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Treister NS, Bruch JM, eds. <i>Clinical Oral Medicine and Pathology.</i> New York: Humana Press; 2010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nystatin-and-triamcinolone-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9713 Version 97.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F202905\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F202894\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F202901\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F202895\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50525681\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50525682\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202884\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F202872\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F202887\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F202886\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202879\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202890\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202876\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299779\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202880\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202881\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14287273\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F202891\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15788598\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202875\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F202889\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524689\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539904\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9713|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nystatin-and-triamcinolone-patient-drug-information\" class=\"drug drug_patient\">Nystatin and triamcinolone: Patient drug information</a></li></ul></div></div>","javascript":null}